| Project/Area Number |
14571521
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | KEIO UNIVERSITY |
|---|
Principal Investigator |
HORIGUCHI Yutaka Keio University, School of Medicine, instructor, 医学部, 助手 (60229234)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MURAI Masaru Keio University, School of Medicine, Professor, 医学部, 教授 (90101956)
NAKASHIMA Jun Keio University, School of Medicine, Assistant Processor, 医学部, 専任講師 (10167546)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2002: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Keywords | prostate cancer / immunotherapy / dendritic cell / prostate specific membrane antigen / cancer targeting therapy / peptide / CTL / HLA-A24 / 前立腺癌特異的膜抗原 |
|---|
| Research Abstract |
Prostate cancer is a significant and growing health problem in the Japanese population, and hormone-refractory disease is known to be highly resistant to the conventional radiotherapy and/or chemotherapy. Therefore, it is important to develop an alternative strategy to treat hormone-refractory prostate cancer patients. Prostate-specific membrane antigen (PSMA), which is a transmembrane glycoprotein predominantly expressed in prostate cancer, is an attractive target for tumor-specific immunotherapy. Because HLA-A24 is the most common MHC class 1 allele among Japanese population, it is of great interest to identify HLA-A24-restricted epitope peptides from PSMA for further application of the dendritic cells (DC)-based immunotherapy targeting of prostate cancer. To identify HLA-A24-restricted epitope peptides, several PSMA-encoded HLA-A24 binding peptides were designed and screened for their capabilities to elicit specific antitumor cytotoxic T-lymphocytes response. These epitopes would be utilized to further evaluate the clinical utility of DC-based immunotherapeutic strategies for treatment of hormone-refractory prostate cancers.
|
